

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>Versant Venture Capital VI, L.P.</u> <hr/> (Last) (First) (Middle) ONE SANSOME STREET, SUITE 1650 <hr/> (Street) SAN FRANCISCO CA 94104 <hr/> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Monte Rosa Therapeutics, Inc. [GLUE]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 09/20/2024	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	09/20/2024		S		1,132,566	D	\$6.5296 ⁽¹⁾	5,099,336	D ⁽²⁾	
Common Stock								2,097,938	I	See Footnote ⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person*
Versant Venture Capital VI, L.P.

 (Last) (First) (Middle)
 ONE SANSOME STREET, SUITE 1650

 (Street)
 SAN FRANCISCO CA 94104

 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Versant Ventures VI GP, L.P.

 (Last) (First) (Middle)
 ONE SANSOME STREET, SUITE 1650

 (Street)
 SAN FRANCISCO CA 94104

 (City) (State) (Zip)

(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
Versant Ventures VI GP-GP, LLC		
(Last)	(First)	(Middle)
ONE SANSOME STREET, SUITE 1650		
(Street)		
SAN FRANCISCO	CA	94104
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
Versant Vantage I, L.P.		
(Last)	(First)	(Middle)
ONE SANSOME STREET, SUITE 1650		
(Street)		
SAN FRANCISCO	CA	94104
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
Versant Vantage I GP, L.P.		
(Last)	(First)	(Middle)
ONE SANSOME STREET, SUITE 1650		
(Street)		
SAN FRANCISCO	CA	94104
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
Versant Vantage I GP-GP, LLC		
(Last)	(First)	(Middle)
ONE SANSOME STREET, SUITE 1650		
(Street)		
SAN FRANCISCO	CA	94104
(City)	(State)	(Zip)

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from \$6.30 to \$6.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

2. Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Each of Versant VI GP-GP and Versant VI GP may be deemed to share voting, investment and dispositive power over the shares held by Versant VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.

3. Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. Each of Versant Vantage I GP-GP and Versant Vantage I GP may be deemed to share voting, investment and dispositive power over the shares held by Versant Vantage I and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.

[Versant Venture Capital VI, L.P. By: Versant Ventures VI GP, L.P. Its: General Partner](#)
[By: Versant Ventures VI GP-GP, LLC Its: General Partner](#) 09/24/2024
[By: /s/ Max Eisenberg Its: Chief Operating Officer](#)
[Versant Ventures VI GP, L.P. By: Versant Ventures VI GP-GP, LLC Its: General Partner](#) 09/24/2024
[By: /s/ Max Eisenberg Its: Chief Operating Officer](#)
[Versant Ventures VI GP-GP, LLC By: /s/ Max Eisenberg Its: Chief Operating Officer](#) 09/24/2024

Versant Vantage I, LP By:
Versant Vantage I GP, L.P. Its:
General Partner By: Versant
Vantage I GP-GP, LLC Its: 09/24/2024
General Partner By: /s/ Max
Eisenberg Its: Chief Operating
Officer

Versant Vantage I GP, L.P.,
By: Versant Vantage I GP-GP,
LLC Its: General Partner By: 09/24/2024
/s/ Max Eisenberg Its: Chief
Operating Officer

Versant Vantage I GP-GP,
LLC, By: /s/ Max Eisenberg 09/24/2024
Its: Chief Operating Officer

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.